← Search & browse all drugs

oxyphenisatine

A06AB01

Forms & Strengths

Historically available as oral tablets (various strengths)
Previously formulated as drops or enemas for cathartic use
Withdrawn from global markets due to hepatotoxicity

Adult Dosing

No longer clinically recommended or approved
Historical constipation dosing: 5 to 10 mg orally at bedtime
Enema preparations historically used 2 to 5 mg

Pediatric Dosing

Contraindicated and not recommended in pediatric populations
Historical use for pediatric constipation has been abandoned due to severe liver toxicity

Indications

Historically indicated for short-term treatment of constipation
Previously used for bowel evacuation prior to diagnostic procedures or surgery
Currently obsolete with no approved clinical indications

Mechanism of Action

Stimulant laxative acting directly on the intestinal mucosa
Increases intestinal motility by stimulating the intramural nerve plexus of the intestinal smooth muscle
Promotes net accumulation of water and electrolytes in the colonic lumen

Contraindications

Hypersensitivity to oxyphenisatine or related triarylmethane laxatives
Symptoms of appendicitis, intestinal obstruction, or undiagnosed abdominal pain
Acute surgical abdomen, ulcerative colitis, or severe dehydration
Pre-existing hepatic disease or history of drug-induced liver injury

Adverse Reactions

Severe hepatotoxicity including acute and chronic active hepatitis
Abdominal cramping, colic, and nausea
Electrolyte disturbances and hypokalemia with chronic use
Cathartic colon and loss of normal bowel function with prolonged abuse

Drug Interactions

Potential enhancement of cardiac glycoside toxicity if hypokalemia occurs
Decreased absorption of concurrently administered oral medications due to accelerated GI transit
Synergistic hepatotoxicity with other known hepatotoxic drugs

Curated Content: Needs Vetting Before Put to Clinical Use